FDMT — 4D Molecular Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1650648 ·
Last close
$12.31
Market Cap
$643.52M
52W High
$14.00
52W Low
$8.07
ADV30
1,092,015
Next earnings
2026-05-07
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 3,047,000 | — | -73,620,000 | -68,760,000 | 512,905,000 | 72,488,000 | 61,069,000 |
| Dec 2025 | 85,090,000 | — | 14,715,000 | 19,397,000 | 566,711,000 | 60,241,000 | 61,047,000 |
| Sep 2025 | 90,000 | — | -61,185,000 | -56,876,000 | 423,982,000 | 48,555,000 | 54,999,000 |
| Jun 2025 | 15,000 | — | -59,456,000 | -54,658,000 | 473,637,000 | 77,159,000 | 52,747,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-109,082,000
Investing CF
$-92,973,000
Financing CF
$112,960,000
CapEx
$-3,424,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.64
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-716,304,000
Inventory
—
Receivables
—
ST Investments
$342,414,000
EBIT TTM
$-159,547,000
Pretax Income TTM
$-140,109,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$88,242,000
EBITDA
$-171,434,000
Free Cash Flow
$-69,357,248
Enterprise Value
$303,483,904
Total Cash
$390,892,000
Total Debt
$20,535,000
Shares Out
52,276,254
Trailing EPS
$-2.57
Book Value
$8.64
ROE
-34.9%
ROA
-21.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 85,209,000 | -159,547,000 | -140,109,000 | 566,711,000 | 61,047,000 | — | -109,082,000 |
| Dec 2024 | 37,000 | -187,841,000 | -160,868,000 | 560,384,000 | 49,778,000 | — | -134,585,000 |
| Dec 2023 | 20,723,000 | -112,867,000 | -100,837,000 | 339,891,000 | 32,062,000 | — | -75,792,000 |
| Dec 2022 | 3,129,000 | -110,032,000 | -107,494,000 | 261,846,000 | 30,509,000 | — | -86,685,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.73
Max Pain — expiry 2026-10-16
max pain strike: $8.00 · spot: $12.31 · call oi: 3,353 · put oi: 66Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AGMB | Agomab Therapeutics NV | $644.16M | $13.08 | — |
| TECX | Tectonic Therapeutic, Inc. | $648.53M | $34.37 | — |
| PRME | Prime Medicine, Inc. | $682.73M | $3.78 | — |
| ALLO | Allogene Therapeutics, Inc. | $690.31M | $2.00 | — |
| CADL | Candel Therapeutics, Inc. | $695.33M | $9.49 | — |
News headlines (Yahoo Finance, 1h cache)
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
2026-06-30 20:05 · Yahoo
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
2026-06-29 12:00 · Yahoo
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
2026-06-29 12:00 · Yahoo
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
2026-06-26 11:30 · Yahoo
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?
2026-06-23 13:42 · Yahoo
4DMT Announces New Employment Inducement Grants
2026-06-12 20:05 · Yahoo
Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight
2026-05-27 12:31 · Yahoo
4DMT to Participate in Upcoming Investor Conferences
2026-05-27 12:00 · Yahoo
4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You?
2026-05-20 12:36 · Yahoo
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy
2026-05-17 00:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.